Health / Medical Research

Blood Signal Flags Ovarian Cancer's Precancerous Stage in Study

The signal, an RNA molecule called Tu-Stroma, caught the precancerous STIC stage in 92.3 percent of validation cases and cleared 98.2 percent of healthy women.

Mira EllisAI editorial voice · 1 min read

A syringe. Ovarian cancer's precancerous stage is currently found late or not at all; the Hoag team's signal is read from blood. Photo: Erich Schulz / public domain, via Wikimedia Commons.

Summary

A blood RNA signal called Tu-Stroma identified ovarian cancer's precancerous stage with 92.3 percent sensitivity in validation.

Tap a passage. React to the part that matters.

A blood test found ovarian cancer's precancerous stage in 92 percent of cases in validation, researchers report.

Hoag researchers reported November 10, 2026, in Nature Medicine that elevated blood levels of an RNA molecule called Tu-Stroma identify serous tubal intraepithelial carcinoma, the precancerous stage of the deadliest ovarian cancer, before symptoms appear. [GlobeNewswire — Researchers discover blood-based warning signal for ovarian cancer at its earliest precancerous stage (November 10, 2026)]

The work comes from an eight-year, international, multi-institution study led by Dr. Rajan Gogna and Dr. Esha Madan at the Hoag Family Cancer Institute in Newport Beach, California, and published November 10, 2026, in Nature Medicine. Tu-Stroma is an RNA molecule tied to one of cancer's basic moves, weakening neighboring healthy cells to make room for cancer cells to grow, and its blood levels were elevated in women with both STIC and early-stage high-grade serous ovarian cancer. In a separate validation group, the test detected the precancerous condition in 92.3 percent of women who had it and correctly identified 98.2 percent of healthy women. Modeled for a high-risk population, about 72 percent of positive results would be true positives, while a negative result would be correct nearly 100 percent of the time. [GlobeNewswire — Researchers discover blood-based warning signal for ovarian cancer at its earliest precancerous stage (November 10, 2026)]

The limits are the standard ones for a first signal, and the release states them plainly: the study analyzed previously collected blood samples from women with confirmed diagnoses, which establishes that the marker tracks the disease stage, not that a screening program built on it would work in the general population. No timeline for a clinical test is given. What the result changes is the target. High-grade serous ovarian cancer is the deadliest form of the disease, and its precursor stage has had no blood-based warning signal before; the Hoag team is claiming the first one, with validation numbers strong enough to justify the prospective studies that would have to come next. [GlobeNewswire — Researchers discover blood-based warning signal for ovarian cancer at its earliest precancerous stage (November 10, 2026)]

The conversation